Published in Antimicrob Agents Chemother on July 01, 2001
Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell (2010) 5.33
Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev (2007) 3.61
A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother (2001) 1.55
Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother (2005) 0.87
Alarmingly High Segregation Frequencies of Quinolone Resistance Alleles within Human and Animal Microbiomes Are Not Explained by Direct Clinical Antibiotic Exposure. Genome Biol Evol (2015) 0.78
Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother (2004) 0.76
Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum. Antimicrob Agents Chemother (2005) 0.76
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol (1969) 8.78
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother (2000) 3.22
Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins. Antimicrob Agents Chemother (1991) 2.82
Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist (1998) 1.80
Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother (1999) 1.75
High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother (2000) 1.75
Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. J Clin Microbiol (2000) 1.66
Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother (1997) 1.46
Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother (1999) 1.39
Anaerobic infections in humans: an overview. Anaerobe (1995) 1.32
Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro. Antimicrob Agents Chemother (1998) 1.31
In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother (1997) 1.27
Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob Agents Chemother (1998) 1.26
PCR-restriction fragment length polymorphism analysis for identification of Bacteroides spp. and characterization of nitroimidazole resistance genes. J Clin Microbiol (2000) 1.20
Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae. Biochem Biophys Res Commun (1998) 1.19
Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci. Antimicrob Agents Chemother (1999) 1.12
Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob Agents Chemother (2000) 1.05
Semi-microtechnique for the biochemical characterization of anaerobic bacteria. J Clin Microbiol (1976) 1.04
Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother (1998) 1.04
Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother (1999) 1.03
Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase. Antimicrob Agents Chemother (1999) 0.98
Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone. Infection (2000) 0.91
A primer on anaerobic bacteria and anaerobic infections for the uninitiated. Infection (1999) 0.84
Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. Support Care Cancer (1999) 0.84
Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? J Antimicrob Chemother (2000) 0.84
Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants. Antimicrob Agents Chemother (1999) 0.83
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother (2000) 4.31
Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis (2001) 4.17
Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet (1977) 4.07
ABC of mental health. Mental health emergencies. BMJ (1997) 3.46
Enhanced detection of bacteremia with a new BACTEC resin blood culture medium. J Clin Microbiol (1983) 3.25
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1984) 3.24
Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: earlier diagnosis or better treatment. BMJ (1997) 3.18
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother (1994) 3.12
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother (2000) 3.00
Staging of gastrulating mouse embryos by morphological landmarks in the dissecting microscope. Development (1993) 2.95
Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis (1999) 2.74
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother (1992) 2.64
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother (1999) 2.63
Susceptibility of anaerobic bacteria to ten antimicrobial agents. Antimicrob Agents Chemother (1978) 2.45
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrob Agents Chemother (1986) 2.39
Evaluation of a two-hour method for screening pathogens from stool specimens. J Clin Microbiol (1984) 2.27
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother (1994) 2.21
Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features. Arch Intern Med (1993) 2.21
Pleuropulmonary infections caused by Eikenella corrodens. Rev Infect Dis (1992) 2.20
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob Agents Chemother (1997) 2.17
Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme. BJOG (2013) 2.16
Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother (1995) 2.13
Comparison of three methods for anaerobe identification. J Clin Microbiol (1983) 2.12
Four methods for identification of gram-negative nonfermenting rods: organisms more commonly encountered in clinical specimens. J Clin Microbiol (1980) 2.09
Accident department or general practice? Br Med J (Clin Res Ed) (1986) 2.08
In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.04
Proctitis associated with Neisseria cinerea misidentified as Neisseria gonorrhoeae in a child. J Clin Microbiol (1985) 1.90
Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids (1991) 1.90
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1996) 1.90
Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother (1997) 1.87
Comparative evaluation of the API 20S system and the automicrobic system gram-positive identification card for species identification of streptococci. J Clin Microbiol (1984) 1.82
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother (1998) 1.79
Evaluation of the rapid strep system for species identification of streptococci. J Clin Microbiol (1984) 1.78
Evaluation of the rapid NFT system for identification of gram-negative, nonfermenting rods. J Clin Microbiol (1984) 1.78
In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 1.75
Pancreatic abscess associated with Achromobacter group Vd biovar 1. J Clin Microbiol (1980) 1.75
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother (1998) 1.73
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother (2010) 1.72
In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.70
Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J Antimicrob Chemother (1993) 1.69
Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucleotide Res (1978) 1.65
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.62
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Antimicrob Agents Chemother (1997) 1.61
Evaluation of the E-Test for susceptibility testing of pneumococci. Diagn Microbiol Infect Dis (1992) 1.59
Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother (1995) 1.58
Classification and properties of 64 multiplexed microsphere sets. Cytometry (1998) 1.58
Accuracy and reproducibility of a four-hour method for anaerobe identification. J Clin Microbiol (1985) 1.54
Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother (1999) 1.52
Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother (1996) 1.51
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother (1994) 1.51
Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother (2001) 1.50
Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother (1994) 1.49
Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother (2000) 1.49
Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother (2000) 1.48
Multiple cancer site comparison of adjusted survival by hospital of treatment: an East Anglian study. Br J Cancer (2000) 1.46
Computerisation of primary care in Wales. BMJ (1991) 1.46
Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother (2001) 1.44
Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother (1994) 1.44
The Opitz syndrome gene product, MID1, associates with microtubules. Proc Natl Acad Sci U S A (1999) 1.44
Pathogenic mechanisms of a non-agglutinable Vibrio cholerae strain: demonstration of invasive and enterotoxigenic properties. Infect Immun (1977) 1.43
Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis (2001) 1.42
Ability of RapID Yeast Plus System to identify 304 clinically significant yeasts within 5 hours. J Clin Microbiol (1996) 1.41
Socioeconomic effects on breast cancer survival: proportion attributable to stage and morphology. Br J Cancer (2003) 1.40
Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob Agents Chemother (1997) 1.37
Oxyrase, a method which avoids CO2 in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by CO2. J Clin Microbiol (1993) 1.36
Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (2000) 1.34
Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob Agents Chemother (1996) 1.34
Evaluation of PCR primers to screen for Streptococcus pneumoniae isolates and beta-lactam resistance, and to detect common macrolide resistance determinants. J Antimicrob Chemother (2001) 1.33
Comparison of three methods for identification of Enterobacteriaceae. Eur J Clin Microbiol (1982) 1.32
Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres. J Antimicrob Chemother (1990) 1.31
Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene (2007) 1.28
Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. J Antimicrob Chemother (1996) 1.27
The fine structure of sarcoid and tuberculous granulomas. Postgrad Med J (1970) 1.27
CD8 is critically involved in lymphocyte activation by a T. brucei brucei-released molecule. Cell (1993) 1.27
Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis (2001) 1.25
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1996) 1.24
Chemical faecal fat using single stools. Scand J Gastroenterol (1971) 1.23
Transduction of R factors in Proteus mirabilis and P. rettgeri. J Gen Microbiol (1973) 1.23
Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother (1994) 1.23
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). Antimicrob Agents Chemother (1997) 1.22
Neonatal septicemia and meningitis due to Aeromonas shigelloides. J Pediatr (1978) 1.21
Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies. J Clin Microbiol (2000) 1.20
Septicemia due to Capnocytophaga (Bacteroides ocharaceus) in Hodgkin's disease. Ann Intern Med (1979) 1.19
Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency. Clin Infect Dis (1995) 1.19
Resistance patterns of streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece. Clin Infect Dis (1997) 1.19
Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother (1996) 1.18
Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. Antimicrob Agents Chemother (1998) 1.18
Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother (2000) 1.16
Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology. Antimicrob Agents Chemother (1997) 1.16
Accuracy and reproducibility of the 4-hour ATB 32A method for anaerobe identification. J Clin Microbiol (1989) 1.15
The effects of therapy with oestriol succinate and ethinyl oestradiol on the haemostatic mechanism in post-menopausal women. Thromb Haemost (1976) 1.14
Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob Agents Chemother (1993) 1.14
Bidirectional activating signals between Trypanosoma brucei and CD8+ T cells: a trypanosome-released factor triggers interferon-gamma production that stimulates parasite growth. Eur J Immunol (1991) 1.14
Purification and characterization of an imipenem hydrolysing metallo-beta-lactamase from Bacteroides fragilis. J Antimicrob Chemother (1992) 1.14
Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole. Antimicrob Agents Chemother (1997) 1.12
Evaluation of the four-hour Micro-ID technique for direct identification of oxidase-negative, Gram-negative rods from blood cultures. J Clin Microbiol (1980) 1.12
Intake and absorption of tocopherol. Ann N Y Acad Sci (1972) 1.12
Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies. J Clin Microbiol (1995) 1.12